带状疱疹药物市场规模、份额、成长分析（按诊断、治疗和预防、按给药途径、按最终用户、按地区）—产业预测 2025-2032

2023 年全球带状疱疹药物市场规模为 22 亿美元，预计将从 2024 年的 24.2 亿美元增长到 2032 年的 51.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 10.0%。

带状疱疹治疗市场持续成长，主要原因是老年族群中带状疱疹的发生率不断上升。人们对带状疱疹后遗症神经痛预防措施和管理的认识不断提高，推动了对疫苗和抗病毒治疗的需求。技术创新，尤其是人工智慧，正在彻底改变研究方向，促进候选药物的快速识别，并改善患者的治疗效果。专注于提高长期免疫力的疫苗临床试验正在增加，尤其是在医疗保健条件改善的发展中地区。然而，儘管带状疱疹的发生率不断上升，但新型疗法的研发管道仍然有限，积极研发的公司寥寥无几。重组带状疱疹疫苗因其持久的疗效和较低的副作用而广受好评，其应用也为市场发展势头做出了积极贡献。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

带状疱疹治疗药物市场规模（按诊断和复合年增长率）（2025-2032）

• 市场概览
• 实验室测试
• 萤光显微镜
• 即时聚合酵素链锁反应（PCR）
• 血清学检测
• 其他的

带状疱疹药物市场规模（依治疗及预防）及复合年增长率（2025-2032）

• 市场概览
• 抗病毒药物
• 药品
• 抗发炎药物
• 抗组织胺药
• 抗惊厥药
• 辣椒素
• 麻醉霜、凝胶和贴片
• 疫苗
• 其他的

带状疱疹药物市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概览
• 口服
• 外用
• 其他的

带状疱疹治疗药物市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院和诊所
• 诊断中心
• 研究和学术机构
• 居家照护环境
• 其他的

带状疱疹治疗药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• GlaxoSmithKline（GSK）（UK）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Sanofi（France）
• Novartis AG（Switzerland）
• Astellas Pharma Inc.（Japan）
• ModernaTX, Inc.（USA）
• Dynavax Technologies Corporation（USA）
• Curevo, Inc.（USA）
• Jiangsu Recbio Technology Co., Ltd.（China）
• Luzhu Biotechnology Co., Ltd.（China）
• Green Cross Corporation（South Korea）
• BioNTech（Germany）
• Bristol-Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• SK bioscience（South Korea）
• Vaxine Pty Ltd（Australia）
• EpiVax（USA）
• Virios Therapeutics（USA）
• WEX Pharmaceuticals Inc.（Canada）

结论和建议

Global Herpes Zoster Therapeutics Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.42 billion in 2024 to USD 5.19 billion by 2032, growing at a CAGR of 10.0% during the forecast period (2025-2032).

The herpes zoster therapeutics market is witnessing consistent growth, largely fueled by the increasing prevalence of shingles in an aging population. A surge in awareness regarding preventive measures and the management of post-herpetic neuralgia is driving demand for vaccines and antiviral treatments. Innovations in technology, particularly AI, are revolutionizing research, facilitating rapid drug candidate identification and enhancing patient outcomes. Clinical trials focused on vaccines that improve long-term immunity are on the rise, especially in developing regions with improved healthcare access. However, the pipeline for new therapies remains limited, with few companies actively pursuing development despite the growing incidence of herpes zoster. The adoption of recombinant zoster vaccines, celebrated for their lasting efficacy and reduced side effects, is also contributing positively to market momentum.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Herpes Zoster Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Herpes Zoster Therapeutics Market Segments Analysis

Global Herpes Zoster Therapeutics Market is segmented by Diagnosis, Treatment and Prevention, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Laboratory Testing, Immunofluorescent Microscopy, Real-Time Polymerase Chain Reaction (PCR), Serological Testing and Others. Based on Treatment and Prevention, the market is segmented into Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Capsaicin, Numbing Creams, Gels, or Patches, Vaccines and Others. Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is being propelled by advancements in Artificial Intelligence, which are enhancing drug discovery processes. Cutting-edge algorithms are adept at sifting through extensive datasets, encompassing genetic, proteomic, and chemical compound libraries, to pinpoint promising antiviral candidates. This innovation significantly lowers both the cost and duration of preclinical and clinical development phases. By 2024, major pharmaceutical companies, such as Pfizer, alongside emerging biotech firms, have adopted AI-driven platforms to expedite research efforts. As a result, this integration is fostering the swift development of next-generation vaccines and treatments for shingles and related complications, including post-herpetic neuralgia (PHN).

Restraints in the Global Herpes Zoster Therapeutics Market

The global market for herpes zoster therapeutics faces significant constraints due to the stringent regulatory frameworks and data privacy issues surrounding the use of patient information for artificial intelligence (AI) algorithm training. In jurisdictions with strict health data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe, the integration of AI in clinical settings is slowed considerably. These regulatory challenges can result in delays for AI-driven innovations, consequently impeding the growth of the market. Consequently, the potential benefits of AI in enhancing herpes zoster therapeutics may be stifled by these compliance-related obstacles.

Market Trends of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is witnessing a significant trend towards the integration of personalized artificial intelligence (AI) models for preventing post-herpetic neuralgia (PHN), a debilitating complication following shingles. These AI-driven approaches analyze various patient-specific factors, including immune response, genetic predispositions, and individual pain thresholds to formulate customized treatment regimens. By employing real-world data, companies like Tempus and IBM Watson Health are enhancing the efficacy of therapeutic interventions, leading to improved patient outcomes. This trend underscores a shift towards precision medicine, driving growth and innovation in the herpes zoster therapeutics landscape as healthcare evolves to meet personalized patient needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Herpes Zoster Therapeutics Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Laboratory Testing
• Immunofluorescent Microscopy
• Real-Time Polymerase Chain Reaction (PCR)
• Serological Testing
• Others

Global Herpes Zoster Therapeutics Market Size by Treatment and Prevention & CAGR (2025-2032)

• Market Overview
• Antiviral Medications
• Narcotic Medications
• Anti-Inflammatory Medications
• Antihistamines
• Anticonvulsants
• Capsaicin
• Numbing Creams, Gels, or Patches
• Vaccines
• Others

Global Herpes Zoster Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• Others

Global Herpes Zoster Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Research & Academic Institutes
• Home Care Settings
• Others

Global Herpes Zoster Therapeutics Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ModernaTX, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curevo, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Recbio Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luzhu Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK bioscience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxine Pty Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EpiVax (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virios Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WEX Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations